Susquehanna International Group, LLP Bio Cardia, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.37 - $1.07 $24,207 - $70,005	65,426 New	65,426 $43,000
Q1 2023 May 16, 2023	SELL	$1.87 - $2.54 $129,273 - $175,590	-69,130 Reduced 61.27%	43,696 $85,000
Q4 2022 Feb 14, 2023	SELL	$1.61 - $32.1 $39,332 - $784,203	-24,430 Reduced 17.8%	112,826 $235,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $30.3 $6,819 - $860,944	28,414 Added 26.11%	137,256 $266,000
Q2 2022 Aug 15, 2022	BUY	$17.7 - $32.55 $646,297 - $1.19 Million	36,514 Added 50.48%	108,842 $161,000
Q1 2022 May 16, 2022	BUY	$21.3 - $39.0 $139,238 - $254,943	6,537 Added 9.94%	72,328 $150,000
Q4 2021 Feb 14, 2022	BUY	$25.65 - $46.05 $564,146 - $1.01 Million	21,994 Added 50.22%	65,791 $128,000
Q3 2021 Nov 15, 2021	BUY	$42.6 - $58.65 $1.87 Million - $2.57 Million	43,797 New	43,797 $138,000
Q4 2019 Feb 14, 2020	SELL	$48.0 - $72.0 $735,168 - $1.1 Million	-15,316 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$51.3 - $94.5 $785,710 - $1.45 Million	15,316 New	15,316 $51,000

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $39.8M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.